HK14294A - Skin improving composition containing gamma-linolenic acid or dihomo-gamma-linolenic acid - Google Patents

Skin improving composition containing gamma-linolenic acid or dihomo-gamma-linolenic acid

Info

Publication number
HK14294A
HK14294A HK142/94A HK14294A HK14294A HK 14294 A HK14294 A HK 14294A HK 142/94 A HK142/94 A HK 142/94A HK 14294 A HK14294 A HK 14294A HK 14294 A HK14294 A HK 14294A
Authority
HK
Hong Kong
Prior art keywords
skin
gla
dgla
smoothness
gamma
Prior art date
Application number
HK142/94A
Other languages
German (de)
English (en)
Inventor
David F. Horrobin
John C.M. Stewart
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10633834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK14294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of HK14294A publication Critical patent/HK14294A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Medicinal Preparation (AREA)

Claims (5)

  1. Utilisation de l'acide γ-linolénique (GLA) ou de l'acide dihomo-γ-linolénique (DGLA) ou des deux, tels quels ou sous la forme de dérivés physiologiquement acceptables et équivalents, dans la fabrication d'une composition cosmétique, en particulier d'une composition orale, pour améliorer la douceur d'une peau normale, en bonne santé ou superficiellement normale, en bonne santé.
  2. Utilisation selon la revendication 1, dans laquelle les quantités de GLA et/ou de DGLA conviennent pour l'administration quotidienne, en particulier l'administration orale, de 1 mg à 100 g, de préférence de 20 mg à 2 g, et plus préférablement de 1 mg à 500 mg, de l'acide ou de chaque acide, ou de quantités molaires équivalentes d'un ou plusieurs dérivés de ceux-ci.
  3. Utilisation selon la revendication 1 pour l'administration locale, dans laquelle le ou les acides sont présents à une concentration de 0,001 à 20 % en poids, de préférence de 0,01 à 10 % en poids, et plus préférablement de 0,05 à 3 % en poids, de l'acide ou de chacun des acides ou de quantités molaires équivalentes d'un ou plusieurs dérivés de ceux-ci.
  4. Procédé de traitement cosmétique pour améliorer la douceur d'une peau normale, en bonne santé, ou superficiellement normale, en bonne santé, par application sur la peau d'une composition comprenant du GLA ou du DGLA ou les deux, tels quels ou sous la forme de dérivés physiologiquement acceptables et équivalents.
  5. Procédé de traitement cosmétique selon la revendication 4 pour améliorer la douceur d'une peau normale, en bonne santé ou superficiellement normale, en bonne santé, par application quotidienne sur la peau d'une composition de 1 mg à 100 g, de préférence de 20 mg à 2 g, et plus préférablement de 1 mg à 500 mg de l'acide ou de chaque acide ou de quantités molaires équivalentes d'un ou plusieurs dérivés de ceux-ci.
HK142/94A 1988-03-22 1994-02-24 Skin improving composition containing gamma-linolenic acid or dihomo-gamma-linolenic acid HK14294A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888806737A GB8806737D0 (en) 1988-03-22 1988-03-22 Therapeutic composition & method

Publications (1)

Publication Number Publication Date
HK14294A true HK14294A (en) 1994-03-04

Family

ID=10633834

Family Applications (1)

Application Number Title Priority Date Filing Date
HK142/94A HK14294A (en) 1988-03-22 1994-02-24 Skin improving composition containing gamma-linolenic acid or dihomo-gamma-linolenic acid

Country Status (13)

Country Link
US (1) US4997657B1 (fr)
EP (1) EP0334507B1 (fr)
JP (1) JPH02149508A (fr)
KR (1) KR890014088A (fr)
AT (1) ATE94386T1 (fr)
AU (1) AU609952B2 (fr)
CA (1) CA1334003C (fr)
DE (1) DE68909077T2 (fr)
GB (1) GB8806737D0 (fr)
HK (1) HK14294A (fr)
IE (1) IE63646B1 (fr)
NZ (1) NZ228330A (fr)
ZA (1) ZA892002B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0253706A (ja) * 1988-08-18 1990-02-22 Kurooda Japan Kk 化粧料組成物
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
CA2119000A1 (fr) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation pour fumeurs
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
NO304009B1 (no) * 1997-02-04 1998-10-12 Gunnar Volden Hudpreparat
FR2765482B1 (fr) * 1997-07-07 2000-12-08 Oreal Utilisation de l'acide y-linolenique pour prevenir le stress oxydatif
JPWO2002083121A1 (ja) * 2001-04-12 2005-01-27 勝守 福本 皮膚環境の改善組成物とその衣服
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
DE10240989A1 (de) * 2002-09-05 2004-03-11 Uwe Klewinghaus Zusammensetzung und deren Verwendung als pharmazeutische oder kosmetische Formulierung zur äußerlichen Anwendung
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
EP1587377A2 (fr) * 2003-01-31 2005-10-26 The Procter & Gamble Company Moyen pour ameliorer l'aspect de tissus keratiniques de mammiferes
WO2004103388A2 (fr) * 2003-05-22 2004-12-02 Bioniche Life Sciences Inc. Insectifuge
CA2436650A1 (fr) * 2003-08-06 2005-02-06 Naturia Inc. Compositions d'acides linoleniques conjugues : synthese, purification et utilisations
JP2006306813A (ja) * 2005-04-28 2006-11-09 Suntory Ltd 肥満細胞増殖抑制剤
WO2006085687A1 (fr) 2005-02-14 2006-08-17 Suntory Limited Préparation contenant de l'acide dihomo-ϝ-linolénique (dgla) au titre de principe actif
JP2006306812A (ja) * 2005-04-28 2006-11-09 Suntory Ltd 好酸球浸潤抑制剤
JP5546087B2 (ja) * 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
DE102007046202A1 (de) * 2007-09-26 2009-04-09 Schmidt-Philipp, Ingo Anwendung von Antioxidantien und ausgewählten Fettsäuren zur Linderung oder Verhütung von Schmerzen und anderer unerwünschter Körperreaktionen
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2012082226A (ja) * 2012-01-25 2012-04-26 Suntory Holdings Ltd 皮膚疾患経口治療または予防剤
ES2784240T3 (es) * 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
JP6214474B2 (ja) * 2014-06-10 2017-10-18 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
JP6203320B2 (ja) * 2016-04-12 2017-09-27 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
JP6462790B2 (ja) * 2017-07-20 2019-01-30 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN120187420A (zh) * 2022-11-15 2025-06-20 株式会社日水 用于减轻或预防过敏性鼻炎或过敏性结膜炎的症状的组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
AU556817B2 (en) * 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions

Also Published As

Publication number Publication date
DE68909077T2 (de) 1994-03-03
KR890014088A (ko) 1989-10-21
EP0334507B1 (fr) 1993-09-15
IE890769L (en) 1989-09-22
AU609952B2 (en) 1991-05-09
ATE94386T1 (de) 1993-10-15
NZ228330A (en) 1993-10-26
AU3122789A (en) 1989-09-28
ZA892002B (en) 1989-11-29
DE68909077D1 (de) 1993-10-21
GB8806737D0 (en) 1988-04-20
EP0334507A2 (fr) 1989-09-27
JPH02149508A (ja) 1990-06-08
CA1334003C (fr) 1995-01-17
IE63646B1 (en) 1995-05-31
US4997657B1 (en) 1995-05-02
EP0334507A3 (fr) 1991-04-17
US4997657A (en) 1991-03-05

Similar Documents

Publication Publication Date Title
EP0334507B1 (fr) Composition améliorant la peau contenant l'acide gamma-linolénique ou l'acide dihomo-gamma-linolénique
EP0440341B1 (fr) Compositions d'acides gras essentiels et thérapie
EP0585026B1 (fr) Utilisation d'acides gras pour augmenter l'absorption intestinale du calcium
JP2796838B2 (ja) 精神分裂症および／または関連した晩発性運動障害の治療のための薬剤を製造する方法
US5888541A (en) Fatty acid treatment
US5580556A (en) Pharmaceutical compositions containing interferons and fatty acids
JPH0369886B2 (fr)
EP0261814B1 (fr) Composé thérapeutique contenant de l'acide gamma linolénique et du calcium sous forme assimilable
EP0416855B1 (fr) Acides gras pour le traitement et la prévention du dommage de la peau causé par la radiothérapie
JPS58159418A (ja) 医薬組成物
EP0409559B1 (fr) Utilisation pharmaceutique des acides gras
NZ247901A (en) Use of gamma-linolenic acid or dihomogamma-linolenic acid for increasing the smoothness of skin
HK1000997B (en) Use of fatty acids for increasing gut calcium absorption

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)